VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 17, 2013) -Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today it is exhibiting at the 8th World Congress of Melanoma in Hamburg, Germany on July 17-20.
Laserwelt, the Company's exclusive distributor for Verisante Aura™ in Germany, Austria and Liechtenstein, will be assisting Verisante to exhibit Aura™ at our booth (No. 18A) at the Congress. Dr. Jason Rivers, a member of the Company's Clinical Advisory Board, will also be chairing a panel discussion at the Congress entitled "Melanocytic nevi: observation or excision," and will give a presentation entitled "Advanced diagnostic devices: do they help in the distinction between those lesions that warrant observation or excision."
Dr. Jason Rivers is a Clinical Professor of Dermatology at the University of British Columbia, and served for seven years as national director of the Canadian Dermatology Association's Sun Awareness Program. His current practice includes cutaneous oncology, general dermatology, laser, and cosmetic dermatology. He has participated in clinical research for more than 20 years and has published more than 130 articles.
"We are excited for the opportunity to be in Hamburg to raise awareness among key opinion leaders by communicating the benefits of using a tool such as Aura™, a rapid Raman spectroscopy system, to assist in diagnosing skin cancer," said Thomas Braun, President & CEO. "Germany is one of the largest markets in Europe for dermatological and skin care devices. Given the incidence rate of skin cancers here is approximately 20 per cent higher than the rest of Europe, we expect Germany to be an important market for Aura™."
Verisante Aura™ is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma, basal cell carcinoma, and/or actinic keratosis when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura™ is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.
About the World Congress of Melanoma
The World Congress of Melanoma was first held in 1985 in Venice and every four years since then has attracted the international melanoma community of researchers and clinicians.
The Congress covers the entire field of melanoma and other cutaneous malignancies. Epidemiology, prevention and early detection of skin cancer shall be evaluated as methods to reverse the current trend of increasing incidences. New diagnostic devices and optical approaches that have improved the diagnostic sensitivity and specificity of detection shall also be discussed extensively.
About Verisante Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.
Verisante Aura™ was awarded Popular Science Magazine's "Best of What's New Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.
The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.